Maxim Group set a $5.00 price objective on Cytori Therapeutics Inc (NASDAQ:CYTX) in a research note released on Thursday morning. The brokerage currently has a buy rating on the biotechnology company’s stock.
A number of other research analysts have also weighed in on the company. ValuEngine upgraded Cytori Therapeutics from a strong sell rating to a sell rating in a report on Thursday, July 13th. Zacks Investment Research upgraded Cytori Therapeutics from a hold rating to a buy rating and set a $1.25 price objective on the stock in a report on Tuesday, July 11th. Finally, B. Riley lowered Cytori Therapeutics from a buy rating to a neutral rating in a report on Tuesday, July 25th.
Cytori Therapeutics (CYTX) traded up 7.53% during midday trading on Thursday, hitting $0.50. 3,050,513 shares of the stock traded hands. The company’s 50 day moving average price is $0.41 and its 200 day moving average price is $0.76. Cytori Therapeutics has a 12 month low of $0.28 and a 12 month high of $2.13. The firm’s market cap is $17.36 million.
Cytori Therapeutics (NASDAQ:CYTX) last announced its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.02). The firm had revenue of $0.90 million during the quarter, compared to analysts’ expectations of $2.23 million. Cytori Therapeutics had a negative net margin of 450.34% and a negative return on equity of 202.62%. The company’s revenue for the quarter was down 18.2% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.43) EPS. Equities research analysts predict that Cytori Therapeutics will post ($0.60) earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Maxim Group Reiterates “$5.00” Price Target for Cytori Therapeutics Inc (CYTX)” was published by Community Financial News and is owned by of Community Financial News. If you are accessing this piece on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this piece can be read at https://www.com-unik.info/2017/10/22/maxim-group-reiterates-5-00-price-target-for-cytori-therapeutics-inc-cytx.html.
Several institutional investors and hedge funds have recently modified their holdings of the business. Sabby Management LLC increased its stake in shares of Cytori Therapeutics by 28.0% in the 2nd quarter. Sabby Management LLC now owns 1,626,807 shares of the biotechnology company’s stock worth $1,789,000 after acquiring an additional 355,504 shares during the last quarter. Perkins Capital Management Inc. increased its stake in shares of Cytori Therapeutics by 99.0% in the 2nd quarter. Perkins Capital Management Inc. now owns 874,896 shares of the biotechnology company’s stock worth $962,000 after acquiring an additional 435,217 shares during the last quarter. Finally, Vanguard Group Inc. increased its stake in shares of Cytori Therapeutics by 81.9% in the 2nd quarter. Vanguard Group Inc. now owns 612,304 shares of the biotechnology company’s stock worth $674,000 after acquiring an additional 275,653 shares during the last quarter. 11.82% of the stock is owned by institutional investors and hedge funds.
About Cytori Therapeutics
Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.
What are top analysts saying about Cytori Therapeutics Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Cytori Therapeutics Inc and related companies.